SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X, a memecoin on the Bitcoin network, is trending as the community rallies around its potential as the first fair-launched meme on Bitcoin L2 with big names and whales watching. Discussions revolve around its strong community, decentralized nature, and the possibility of reaching $1, with some highlighting its role in driving demand for Bitcoin blockspace. The 'DOG Army' is actively promoting the token, emphasizing its unique position within the Bitcoin ecosystem.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending amid speculation of a potential licensing deal with AstraZeneca and positive sentiment surrounding its cancer drug, ivonescimab. The community is actively discussing the possibility of a significant upfront payment and the potential for the drug to challenge existing treatments. Anticipation is building as investors await further news and data releases, with some highlighting the stock's high short interest as a catalyst for a potential squeeze.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending as community members rally around its potential to become the leading memecoin on the Bitcoin network, with some suggesting it could surpass Dogecoin. Key talking points include its fair launch, decentralized nature, and strong community backing. Many believe it's poised for significant growth and exchange listings.

This platform is engineered to unlock the full potential of Real-World Assets (RWAs) by bringing them onto the XRP Ledger with unparalleled efficiency. Our purpose is to democratize access to high-value assets by providing a streamlined, end-to-end solution for tokenization. Functionally, we offer tools for asset verification, compliant legal wrapping, and the minting of RWA tokens. The project's core utility is twofold: for asset owners, it unlocks immediate liquidity and access to global capital markets; for investors, it offers fractional, transparent, and liquid access to investment classes like private equity and infrastructure bonds. We leverage the XRPL's native speed and built-in DEX to ensure low-cost transactions and instant settlement, setting a new standard for RWA interoperability and finance.

VOLT

VOLT ($XVM.X) is trending as a potential Real World Asset (RWA) coin, drawing comparisons to $XRP.X and $XLM.X. The community highlights its low market cap and potential for integration with the XRP ledger, viewing it as an early opportunity. Community members are actively discussing where to buy the coin and sharing enthusiasm for its potential gains.

Sapien is an open protocol for sourcing verified human knowledge at scale. Its network of millions of contributors spans more than 100 countries, ranging from doctors and engineers to artists and students. Together they produce high-quality AI training data, validated through Sapien’s onchain Proof of Quality system. This ensures enterprises and AI developers can access trusted, human-in-the-loop data while transforming fragmented online work into a sustainable, reputation-based profession. Incentives across the network are powered by the $SAPIEN token, an ERC-20 asset on Base.

Sapien

Sapien.X is trending as the community discusses its potential for significant gains, with some drawing comparisons to other recently successful tokens. The token's chart setup and appealing levels are generating interest, while others speculate about potential scams. The recent listing and overall market conditions abroad are also being mentioned as potential catalysts.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending as traders discuss its low float and potential for a significant price surge, reminiscent of other recent low float runners. Community members are highlighting the stock's scarce shares and growing watcher count, suggesting a possible squeeze. Some are pointing to a recent land sale that could boost NAV.

Numeraire

Numeraire is trending as traders discuss a recent investment from a major US bank into the AI-based crypto hedge fund, which some believe could lead to significant growth. The community is actively analyzing price charts, identifying potential breakout points, and anticipating further upward momentum. With a relatively low circulating supply, many are speculating on substantial long-term gains.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

BBBY is trending as the ticker reactivates, sparking confusion and discussion among traders about Overstock's acquisition of the Bed Bath & Beyond brand and its implications for previous shareholders. The community is actively debating the company's future, potential partnerships, and the possibility of a short squeeze, drawing comparisons to the $GME saga. Some investors express skepticism, citing past financial difficulties, while others see potential in the company's blockchain initiatives.

Tidal Trust III - Fundstrat Granny Shots US Large Cap ETF

Fundstrat Granny Shots US Large Cap ETF

The Fundstrat Granny Shots US Large Cap ETF ($GRNY) is trending as investors discuss its holdings and recent performance, with many referencing Tom Lee's bullish outlook and stock-picking strategy. Community members are weighing the ETF's expense ratio against its potential for long-term growth and diversification, with some speculating about future inclusion of specific assets. The ETF is gaining traction as a way to invest in multiple key investment themes and is being compared to benchmark indexes.

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Resmed Inc.

ResMed ($RMD) is trending amid speculation about a potential buyout or partnership with Incannex ($IXHL), driven by positive clinical trial data for a sleep apnea pill that could disrupt the CPAP market. The community is closely watching for an announcement, especially given that a ResMed executive is on Incannex's advisory board, with some speculating this is a strategic move before Phase 3 trials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Corvus Pharmaceuticals, Inc. (CRVS) traded 30% higher on Friday afternoon after Oppenheimer raised its price target on the stock to $17 from $15, while keeping an ‘Outperform’ rating on the stock.The brokerage cited <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-announces-data-cohorts-1-3-placebo">positive</a> results from a clinical trial announced by the company on Thursday, as per TheFly. Corvus announced new interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.The data demonstrated a favorable safety and efficacy profile, particularly in cohort 3, where patients received higher doses of 200 mg twice daily, the company said.The update continues to support Oppenheimer's enthusiasm for the candidate in this potential blockbuster indication. The firm views these data as highly competitive with Dupilumab and other systemic options for patients with atopic dermatitis.Oppenheimer’s new price target implies a 407% upside to the stock’s closing price of $3.35 on Thursday.Corvus on Thursday reported a first-quarter loss of $0.13 per share, marginally higher than the loss of $0.12 reported in the corresponding period of 2024, and above an estimated loss of $0.12, as per Finchat data.The company ended the quarter with cash, cash equivalents, and marketable securities of $44.2 million compared to $52.0 million as of Dec. 31, 2024, which it expects will fund operations into the fourth quarter of 2026.On Stocktwits, retail sentiment around Corvus rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_12_10_36_PM_png_c210c7fe04.webp" alt="CRVS's Sentiment Meter and Message Volume as of 12:10 p.m. ET on May 9, 2025 | Source: Stocktwits" width="626" height="62"><figcaption>CRVS's Sentiment Meter and Message Volume as of 12:10 p.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CRVS">CRVS stock</a> is down by about 20% this year but up by about 115% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/inspiremd-reports-wider-than-expected-q1-loss/chiWwLoRblh">InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased

Corvus announced new interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.

Equity

Corvus announced new interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.


Shares of Corvus Pharmaceuticals, Inc., fell in Tuesday's extended trading hours after the company posted financial results below Wall Street expectations, although retail traders remained optimistic.The pre-revenue biotech posted an adjusted fourth-quarter (Q4) loss of $0.18 per share, steeper than the expected $0.12 loss.&nbsp;Research and development expenses in the reported quarter rose to $6 million from $4 million a year earlier, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma.R&amp;D expenses climbed to $19.4 million for the full year from $16.5 million in 2023."We continue to advance our selective ITK inhibitor, soquelitinib, in a range of diseases," said CEO Richard Miller.Preclinical data supports its potential in a range of conditions, including solid tumors, autoimmune disorders such as ALPS and systemic sclerosis, as well as inflammatory diseases like asthma and psoriasis.Corvus is nearing complete enrollment in the third cohort of its Phase 1 atopic dermatitis trial, while its Phase 3 trial in peripheral T-cell lymphoma (PTCL) is enrolling patients across multiple sites.&nbsp;The company recently launched a Phase 2 trial for ALPS and plans to initiate a solid tumor study in the third quarter of 2025.As of Dec. 31, 2024, Corvus held $52 million in cash, cash equivalents, and marketable securities, up from $27.1 million a year ago, which it expects to fund operations into the first quarter of 2026.On Stocktwits, sentiment for Corvus flipped into 'extremely bullish' territory from 'bearish' a day ago, accompanied by a 1,000% spike in message volume.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/CRVS_sentiment_and_message_volume_as_of_March_25_png_2347150685.webp" alt="CRVS sentiment and message volume as of March 25.png" width="1318" height="302"><figcaption>CRVS sentiment and message volume as of March 25. | source: Stocktwits</figcaption></figure>One user was bullish after the company's chief executive said the full data for the first three cohorts of its atopic dermatitis trial would be presented at the Society for Investigative Dermatology (SID) Annual Meeting in San Diego in May.<stembedurl>https://stocktwits.com/WalterBean/message/609216709</stembedurl>Another retail watcher expects the stock to close above $4 on Wednesday.<stembedurl>https://stocktwits.com/tradingjunk321/message/609231445</stembedurl>Corvus stock is down more than 28% this year but has more than doubled over the past 12 months. According to Koyfin, out of the six analysts covering the stock on Wall Street, five rate it 'buy' and one rates it 'strong buy.'For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger

Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma. 

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) (Corvus) on behalf of the companys shareholders. The investigation seeks to determine whether Corvus...

Corvus Pharmaceuticals, Inc. to Post FY2024 Earnings of ($0.35) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday...

Corvus Pharmaceuticals (NASDAQ:CRVS) Rating Reiterated by Mizuho

Mizuho restated their neutral rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS - Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. Mizuho currently...

Hold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing Concerns

Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Corvus Pharmaceuticals (CRVS Research Report) on March 26 and set a price...

Mizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)

Corvus Pharmaceuticals (NASDAQ:CRVS  Get Free Report)s stock had its neutral rating restated by equities research analysts at Mizuho in a research report issued to clients...

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Figure 1

 Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for Peripheral T Cell Lymphoma. The plot shows the best percent change in...

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage...

Comparing Corvus Pharmaceuticals (NASDAQ:CRVS) & Anebulo Pharmaceuticals (NASDAQ:ANEB)

Anebulo Pharmaceuticals (NASDAQ:ANEB  Get Free Report) and Corvus Pharmaceuticals (NASDAQ:CRVS  Get Free Report) are both small-cap medical companies, but which is the superior...

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

CRVS
Corvus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRVS News

CRVS Corvus Pharmaceuticals Inc